ELI LILLY & Co

ELI LILLY & Co (LLY) — Investment Memo

🐂 The Bull Case (Warren's voice)

We aren't buying a pharmacy; we're buying a toll bridge on the road to metabolic health.

• The "Modern Coca-Cola" of Health: GLP-1s (Zepbound/Mounjaro) have transitioned from "medicine" to "lifestyle necessity." When a product creates a visible, life-altering result for the affluent, pricing power becomes nearly absolute.
• The ROE Engine: An increase in ROE from 19.5% to 77.8% is not a fluke; it is the sound of a business finding a massive, untapped vein of gold. They are generating staggering returns on the capital they deploy.
• The Ecosystem Moat: Patents provide the legal monopoly, but the manufacturing complexity provides the physical moat. Scaling the production of these biologics is a nightmare; Lilly's ability to build the plants is as much a moat as the molecule itself.
• Attractive Entry: This becomes a Berkshire-grade investment when the market stops pricing it as a "tech moonshot" and starts pricing it as a "cash-flow compounder." We want it when the excitement fades, but the prescriptions keep climbing.

🐻 The Bear Case (Charlie inverts)

“Show me where I’ll die and I won’t go there.”

• The "Washington" Hammer: The most likely death blow. If the US government mandates price caps on obesity drugs or Medicare aggressively negotiates GLP-1 pricing, the projected margins vanish. The government is the only customer that can break a monopoly by decree.
• The Biological Black Swan: A systemic, delayed-onset side effect (e.g., unexpected thyroid malignancy or severe muscle wasting) emerges in the general population. A mass recall doesn't just hit revenue; it destroys the brand and triggers a litigation avalanche.
• The Patent Cliff: Pharma is a treadmill. The moment the GLP-1 patents expire, the revenue doesn't drift—it falls off a cliff. If the "manic" acquisition spree doesn't produce a successor molecule of equal magnitude, the business shrinks overnight.
• The Most Likely Threat: Regulatory pricing intervention. Timeframe: 1–4 years. The political optics of "expensive weight-loss drugs" are poisonous.

💰 Valuation & Margin of Safety

The market is currently pricing in a miracle; we price in a business.

• Intrinsic value estimate: $491.33 per share.
• 25% margin of safety entry: $368.50 (conservative).
• 50% margin of safety entry: $245.67 (Buffett's ideal).
• Current Status: Grossly Expensive. With the stock trading significantly above the $800 mark, the market is pricing in growth far beyond the 8% FCF assumption used in our DCF. We are paying for the next decade of perfection today.

Verdict: PASS

The moat is a fortress, but the price is a fantasy. The gap between our intrinsic value of $491.33 and the current market price creates zero margin of safety. We wait for the inevitable correction or a regulatory shock to bring the price back to reality.